PRISTIQ® How Supplied/Storage and Handling

(desvenlafaxine succinate)

16 HOW SUPPLIED/STORAGE AND HANDLING

PRISTIQ (desvenlafaxine) extended-release tablets are available as follows:

25 mg, tan, square pyramid tablet debossed with "W" (over) "25" on the flat side

 
NDC 0008-1210-30, bottle of 30 tablets in unit-of-use package

50 mg, light pink, square pyramid tablet debossed with "W" (over) "50" on the flat side

 
NDC 0008-1211-14, bottle of 14 tablets in unit-of-use package
 
NDC 0008-1211-30, bottle of 30 tablets in unit-of-use package
 
NDC 0008-1211-01, bottle of 90 tablets in unit-of-use package
 
NDC 0008-1211-50, 10 blisters of 10 (HUD)

100 mg, reddish-orange, square pyramid tablet debossed with "W" (over) "100" on the flat side

 
NDC 0008-1222-14, bottle of 14 tablets in unit-of-use package
 
NDC 0008-1222-30, bottle of 30 tablets in unit-of-use package
 
NDC 0008-1222-01, bottle of 90 tablets in unit-of-use package
 
NDC 0008-1222-50, 10 blisters of 10 (HUD)

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively.

Find PRISTIQ® medical information:

Find PRISTIQ® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRISTIQ® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

How Supplied/Storage and Handling

16 HOW SUPPLIED/STORAGE AND HANDLING

PRISTIQ (desvenlafaxine) extended-release tablets are available as follows:

25 mg, tan, square pyramid tablet debossed with "W" (over) "25" on the flat side

 
NDC 0008-1210-30, bottle of 30 tablets in unit-of-use package

50 mg, light pink, square pyramid tablet debossed with "W" (over) "50" on the flat side

 
NDC 0008-1211-14, bottle of 14 tablets in unit-of-use package
 
NDC 0008-1211-30, bottle of 30 tablets in unit-of-use package
 
NDC 0008-1211-01, bottle of 90 tablets in unit-of-use package
 
NDC 0008-1211-50, 10 blisters of 10 (HUD)

100 mg, reddish-orange, square pyramid tablet debossed with "W" (over) "100" on the flat side

 
NDC 0008-1222-14, bottle of 14 tablets in unit-of-use package
 
NDC 0008-1222-30, bottle of 30 tablets in unit-of-use package
 
NDC 0008-1222-01, bottle of 90 tablets in unit-of-use package
 
NDC 0008-1222-50, 10 blisters of 10 (HUD)

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Each tablet contains 38 mg, 76 mg or 152 mg of desvenlafaxine succinate equivalent to 25 mg, 50 mg or 100 mg of desvenlafaxine, respectively.
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.